Back | Next |
home / stock / drma / drma message board
Subject | By | Source | When |
---|---|---|---|
$DRMA Price gaining | Awl416 | investorshub | 04/22/2023 7:48:52 AM |
$DRMA must see | reena969 | investorshub | 04/20/2023 2:11:59 PM |
Dermata Announces Receipt of Type C Meeting Response | subslover | investorshub | 04/20/2023 12:45:07 PM |
Ridiculous | Awl416 | investorshub | 04/20/2023 10:20:01 AM |
$DRMA short squeeze article | makinezmoney | investorshub | 04/20/2023 12:30:24 AM |
Buyer stepped in triggering those robots | Awl416 | investorshub | 04/19/2023 5:48:55 PM |
Thanks on $DRMA 3.75 exit. There is | reena969 | investorshub | 04/18/2023 4:40:44 PM |
Scary part is within a week the daily | Awl416 | investorshub | 04/18/2023 4:37:10 PM |
Thanks so much :) | subslover | investorshub | 04/18/2023 2:47:36 PM |
https://investorshub.advfn.com/boards/read msg.aspx?message id=171711654 | TheFinalCD | investorshub | 04/18/2023 2:13:24 PM |
As of February 17, 2023, the number of | subslover | investorshub | 04/18/2023 2:11:38 PM |
Buy ther, same jump like drma | Jayzp | investorshub | 04/18/2023 2:08:20 PM |
znewcar1: $DRMA 129% v30,4M Hod3.93 gapN? | znewcar1 | investorshangout | 04/18/2023 1:42:21 PM |
Massive buying attack! | subslover | investorshub | 04/18/2023 1:40:26 PM |
huge run.... | TheFinalCD | investorshub | 04/18/2023 12:59:21 PM |
$3.68 RETEST!!! | reena969 | investorshub | 04/18/2023 12:59:00 PM |
Sorry I have to leave but YS is | reena969 | investorshub | 04/18/2023 12:46:52 PM |
https://stockcharts.com/h-sc/ui?s=drma&p=D&yr=0&mn=6&dy=0&id=p38090673899 htt | surf1944 | investorshub | 04/18/2023 12:44:48 PM |
The algorithm is not in full affect until | reena969 | investorshub | 04/18/2023 12:43:36 PM |
Retest $3.68 everyone READY?? We still have | reena969 | investorshub | 04/18/2023 12:41:04 PM |
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...